Document:

Exhibit 10.2

   

  [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is not material and would likely
    cause competitive harm to the registrant if publicly disclosed.

   

  STRATEGIC PARTNERSHIP AGREEMENT 

   

  BETWEEN

   

  ZYMERGEN INC.

   

  AND

   

  SUMITOMO CHEMICAL CO. LTD.

   

  

  
     

    
      
 

  

  
   

  STRATEGIC PARTNERSHIP AGREEMENT

   

  This Strategic
        Partnership Agreement (this “Agreement”) is made and entered into on April 9, 2019 (the “Effective Date”) between Zymergen Inc., a Delaware
    corporation with offices located at 5980 Horton Street, Suite 105, Emeryville CA 94608 (hereafter “Zymergen”) and Sumitomo Chemical Co. Ltd., a Japanese corporation, with offices located at 27-1, Shinkawa 2-chome, Chuo-ku. Tokyo 104-8260, Japan (hereafter “Sumitomo”). Zymergen and Sumitomo are each referred to herein by name or, individually, as a “Party” or, collectively, as the “Parties”.

   

  Background

   

  Based on Zymergen’s introduction of its biomolecule development capabilities to Sumitomo, the Parties discussed in the autumn of 2017 a joint effort to
    develop polyimide films for [***]. Sumitomo delivered technical targets, and Zymergen initiated a polymer development project from early 2018, subject to a Memorandum of Understanding, which was signed between the Parties on 20th February 2018 (the “1st MOU”);
    in addition to the first objective in the initial development effort, to achieve the technical targets, the second objective was to confirm the potential effectiveness of using [***] [***] to reach specific performance characteristics. Through the two
    review meetings in September and October 2018, the Parties concluded that the intermediate targets set on 1st October 2018 had been largely achieved by the developed
    polymer, which was deemed to be sufficient to establish the proof-of-concept, that [***] offer great opportunities for material innovation beyond the accessible range with synthetic chemistry. The Parties subsequently entered into a second Memorandum
    of Understanding, which was signed between the Parties on 13th February 2019 superseding the 1st
    MOU (the “2nd MOU”) in which the Parties outline a collaboration to partner and develop products, including
    the products initially developed under the 1st MOU.

   

  In consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereby agree as follows:

   

  1.            Definitions and Interpretation.

   

  1.1           Definitions. All
    capitalized terms used but not otherwise defined in this Agreement shall have the meanings set forth on Exhibit A attached hereto:

   

  1.2           Interpretation. In this Agreement, (a) words importing the singular include the plural and vice versa; (b) words importing a gender include all other genders; (c) the word “person” includes a
    reference to a corporation; (d) headings are for convenience only and shall not affect the interpretation of this Agreement; (e) all monetary amounts referred to in this Agreement shall be deemed to be in United States dollars; (f) the appendices,
    exhibits and background form part of this Agreement; (g) a reference to a statute, regulation or provision of a statute or regulation includes a reference to that statute, regulation or provision as amended or re-enacted; and (h) the words “includes”
    and “including” are not words of limitation.

   

  1.3           Order of Precedence. To the extent any terms or provisions of a Project Plan conflict with the terms and provisions of this Agreement, the terms and provisions of this

   

  

  
    1 

    
      
 

  

   

  Zymergen - Sumitomo Strategic
        Partnership Agreement

   

  Agreement shall control, except to the extent such Project Plan specifically states the Parties” intent that such Project Plan control with respect to a
    particular matter.

   

  2.             Project Plans; MOU Intellectual Property

   

  2.1           Agreement Overview. Through this Agreement, the Parties wish to establish a structure and operating mode between both Parties in which the potential of Zymergen’s technology, through bioreachable
    molecules, is maximized in innovation for certain materials and applications of strategic interest to Sumitomo. The scope and specific terms governing the research and development efforts for each Zymergen Development Item and Sumitomo Development Item
    shall be set forth in a written plan in substantially the form set forth in Exhibit B (each such written plan, a “Project Plan”). Each time
    that the Parties are considering engaging in a new development project for a particular Zymergen Development Item and Sumitomo Development Item under the terms and conditions of this Agreement, the Parties shall prepare a draft Project Plan (each, a “Project Proposal”). Each development project shall be subject to all of the terms and conditions of this Agreement, in addition to the specific details
    set forth in the applicable Project Plan.

   

  2.2           Project Plans; Scope Changes. If during the Development Term for a given Project Plan, either Party requests that (a) changes be made to the activities, Deliverables, Development Term or other
    parameters or criteria of such Project Plan or (b) certain activities or Deliverables be added to or removed from the scope of such Project Plan, then the Joint Steering Committee shall discuss such requested change to such Project Plan and make a
    non-binding recommendation to the Parties as to whether to make such requested change. If the Parties agree upon any such changes, then the Parties shall amend the applicable Project Plan in writing to reflect such changes, and to include any other
    details as may be necessary regarding the new or amended activities, Deliverables or parameters.

   

  2.3           MOU Intellectual Property. The Parties have developed Inventions and Intellectual Property Rights under the 1st MOU
    and the 2nd MOU. As set forth in the 2nd MOU, Inventions and Intellectual Property Rights
    that were invented and/or reduced to practice solely by Zymergen under the 1st MOU and prior to the Parties’ work under a given Project Plan are owned by Zymergen (“Zymergen 1St MOU IP”) and,
    therefore, are Background Technology of Zymergen. The Parties hereby agree that Inventions and Intellectual Property Rights developed under the 1st MOU and prior to the
    Parties’ work under a given Project Plan, other than Zymergen 1st MOU IP, shall be treated as Inventions and Intellectual Property Rights developed under an applicable
    Project Plan to the extent, in the latter case, such Inventions and Intellectual Property Rights are referenced in the Project Plan.

   

  3.             Business Models; Project Proposals for
        Development Items

   

  3.1           Business Models. The Parties will decide on the business model, if any, including possible business exclusivity in a defined
    field, for successfully developed Sumitomo Development Items incorporating successfully developed Zymergen Development Items on a case-by-case basis, given the wide variety of possibilities, in accordance with the decision-making process set forth in
    each Project Plan. As a basic principle, one element of this discussion will be a value chain analysis, and a fully considered business model will be used to warrant that the

   

  

  
    2 

    
      
 

  

   

  Zymergen - Sumitomo Strategic Partnership Agreement

   

  benefit sharing between the Parties is fair, such that neither Party should benefit disproportionately relative to its contributions to development items
    and Applications therefor.

   

  3.2           Project Proposals for Development Items. The following issues will be discussed in connection with a new development item and the development of each Project Proposal:

   

  3.2.1        Description of the technical state of the art,
    technical trends and unmet needs;

   

  3.2.2        Description of the desired Zymergen Development
    Item(s) and Sumitomo Development Item(s), including the contribution of each to Applications innovation;

   

  3.2.3        Estimation of market size and business potential
    in case of successful development;

   

  3.2.4        Value chain break down;

   

  3.2.5        Business model and value sharing proposal, where
    a typical model will be Zymergen having the primary right to sell an intermediate product (molecule or polymer), the Zymergen Development Item, to Sumitomo and Sumitomo having the primary right to sell a final product, the Sumitomo Development Item, to
    the end market in the applicable Field, with a profit-sharing mechanism (as referenced in Section 7.1), in each case, to establish fair benefit sharing;

   

  3.2.6        Technical program, including milestones,
    development costs and cost sharing (as referenced in Section 7.1); and

   

  3.2.7        Additional Intellectual Property Rights and
    Inventions arrangements, if any.

   

  3.3           [***] within Field; [***] outside Field. The cooperation between the Parties will be [***] within the applicable Field for the Sumitomo Development ltem(s) and Zymergen Development Item(s) accepted by the JSC in connection with a Project Plan.
    For other uses (a) within the scope of each Party’s Primary Business or (b) related to either an existing Sumitomo Development Item or existing Zymergen Development Item for use outside of the applicable Field, the Parties will [***] on interest (either through the JSC or otherwise) and have [***]
    on any such proposed or existing Sumitomo Development Item or Zymergen Development Item, as applicable. For purposes of this Section 3.3, “Primary Business”
    means (x) with respect to Sumitomo, [***] and (y) with respect to Zymergen, microbial strain development and fennentation-based manufacturing.

   

  4.             Management and Governance.

   

  4.1          Joint Steering Committee.

   

  4.1.1        General. Promptly following the Effective Date, the Parties will establish a
    committee that will be responsible for overseeing the performance of the Project Plans and

   

  

  
    3 

    
      
 

  

   

  Zymergen - Sumitomo Strategic Partnership Agreement

   

  providing strategic guidance in connection with the Project Plans (such committee, the “Joint
          Steering Committee” or “JSC”). The JSC may be set at either four (4) members, two from each Party, or six (6) members, three (3) from each Party, in the discretion of the
    JSC. The JSC shall initially consist of four (4) members, two (2) from each Party. Each Party may substitute or replace its respective representatives at any time by providing written notice to the other Party; provided that such
    substitution or replacement is of sufficient organizational seniority and qualification. Without limiting the generality of the foregoing, the JSC shall be responsible for the following issues; (a) the overall effectiveness and success of the strategic
    cooperation; (b) the total project portfolio management; (c) approval of Project Proposals, judging the scope, attractiveness and contents of Project Proposals; and (d) Project Plan review.

   

  4.1.2        Meetings. The Joint Steering Committee shall convene by telephone conference or in person at least once each calendar quarter. A secretary shall keep a written record of the minutes of the meeting,
    including any formal action taken by the JSC, which will be subject to approval at the next subsequent meeting of the JSC (or sooner, if by written or email consent by each of the members of the JSC). The JSC may take any action permitted to be taken
    by the JSC by unanimous written or email consent, outside of the regular in-person or telephonic meetings described above.

   

  4.1.3        Decision Making; Voting. Each Party shall have one (1) vote in any matter requiring the Joint Steering Committee’s action or approval, and all decisions of the Joint Steering Committee shall require
    unanimous agreement of the Parties. The Joint Steering Committee shall make all decisions and take other actions in good faith and with due care, after consideration of the information that is reasonably available to it; provided that
    if the Joint Steering Committee cannot agree on any matter within its decision-making authority, then either Party may submit the matter for resolution in accordance with Article 11. For clarity, except as specifically set forth herein, the
    Joint Steering Committee shall not have the power to determine or waive compliance with the obligations of this Agreement.

   

  4.1.4        Initial Membership. The initial composition of the Joint Steering Committee shall as follows:

   

  Sumitomo appointees: [***]

   

  Zymergen appointees: Mr. Richard Pieters and Mr. Chris Schroeder.

   

  4.2           Project Co-Leaders.

   

  4.2.1        General. Promptly
    following the Effective Date and promptly following the execution of each additional Project Plan entered into after the Effective Date, Sumitomo and Zymergen will each appoint a project co-leader to oversee the general management and day-to-day
    governance of the applicable Project Plan (each, a “Project Co-Leader”). The Project Co-Leaders will serve as the primary point of contact for the
    Parties regarding the activities contemplated by this Agreement and under each applicable Project Plan, and they shall work together to facilitate the performance of all such activities. Each Party may substitute or replace its respective Project
    Co-Leader at any time by providing written notice to the other Party; provided that such substitution or replacement is at least of substantially equivalent organizational seniority and qualification.

   

  
    4 

    
      
 

  

   

  Zymergen - Sumitomo Strategic Partnership Agreement

   

  4.3          Governance Expenses. Each Party will bear its own costs with respect to (a) its Project Co-Leaders and
      (b) its representatives’ participation on the Joint Steering Committee.

   

  5.             Background
        Technology

   

  5.1           Sumitomo Background Technology. Sumitomo shall own and retain all title, rights and interest in and to Sumitomo Background Technology. Except as specified in Section

      5.3.1,  (a) Sumitomo shall not be under any obligation to make Sumitomo Background Technology
    available to Zymergen and (b) neither Zymergen nor its Affiliates shall have any rights to, or licenses under, Sumitomo Background Technology.

   

  5.2           Zymergen Background Technology. Zymergen shall own and retain all title, rights and interest in and to Zymergen Background Technology. Except as specified in Section

      5.3.2,  (a) Zymergen shall not be under any obligation to make Zymergen Background Technology
    available to Sumitomo and (b) neither Sumitomo nor its Affiliates shall have any rights to, or licenses under, Sumitomo Background Technology.

   

  5.3           Background
        Technology Cross-License.

   

  5.3.1        Sumitomo Background Technology. Subject to the terms and conditions of this Agreement and each Project Plan to be agreed separately between the Parties,
    Sumitomo, on behalf of itself and its Affiliates, will grant to Zymergen a worldwide, fully paid up, non-exclusive, royalty-free, non-transferable (except in accordance with Section 13.6) and non- sublicensable license under the applicable
    Sumitomo Background Technology to: (a) develop the applicable Zymergen Development Item(s); and (b) to make or have made, use, offer to sell, sell, and import the applicable Sumitomo Development Items(s) and Zymergen Development Item(s) in the
    applicable Field. The rights to be granted under this Section 5.3.1 do not cover manufacturing activities that Zymergen undertakes as a foundry for a Third Party.

   

  5.3.2        Zymergen Background Technology. Subject to the terms and conditions of this Agreement and each Project Plan to be agreed separately between the Parties,
    Zymergen, on behalf of itself and its Affiliates, will grant to Sumitomo a worldwide, fully paid up, non-exclusive, royalty-free, non-transferable (except in accordance with Section 13.6) and non-sublicensable license under the applicable
    Zymergen Background Technology to: (a) develop the applicable Sumitomo Development item(s); and (b) make and have made, use, offer to sell, sell, and import the applicable Sumitomo Development Items(s) and Zymergen Development ltem(s) in the applicable
    Field. The rights to be granted under this Section 5,3.2 do not cover manufacturing activities that Sumitomo undertakes as a foundry for a Third Party.

   

  6,             Foreground
      IP

   

  6.1           Guiding Principles. The Parties understand the value of partnering with each other and desire to share in the business opportunities associated with the
    Foreground IP developed

   

  

  
    5 

    
      
 

  

   

  Zymergen - Sumitomo Strategic Partnership Agreement

   

  under this Agreement. [***].

   

  6.2           [***] [***]. Regardless of [***], each [***] in and to  [***] relating to Sumitomo [***] and Zymergen  [***] (the “[***]”).

     

  6.3           Rights to Use [***]. Each Party will have the right, subject to the terms of this Agreement
    (including Sections 3.3 and Articles 6 and 7), to use [***] to make, have made, use, offer to sell, sell, and import applicable
    Sumitomo Development Item(s) and applicable Zymergen Development Item(s) and [***]. Each Party hereby unconditionally and irrevocably waives any right it
    may have, under the applicable law of any nation, as a [***] to require such consent. Each Party will, and hereby does, [***] and shall cause its Affiliates and its Affiliates’ respective Representatives [***] to

    the other Party and its permitted successors and assigns, [***] [***]
      as is necessary to fully effect the [***] thereof as provided in this Section 6.3. Except as otherwise expressly provided in this Agreement,
    under no circumstances shall a Party, as a result of this Agreement, obtain any ownership interest or other right, title, or interest in or to any other Intellectual Property Rights, Invention or Confidential Information of the other Party, whether by
    implication, estoppel, or otherwise, including any items Controlled or developed by the other Party, or delivered by the other Party, at any time pursuant to this Agreement. Notwithstanding anything in this Agreement to the contrary, neither Party
    shall [***] to a Third-Party unless such Party is [***] with

    the explicit written consent of the other Party, including the granting of any pure IP licenses apart from Commercialization activities.

   

  6.4           Commercial Agreement. Upon expiration or termination of the applicable Development Term, the Parties shall initiate good faith discussions to enter into a definitive agreement (each, a “Commercial Agreement”) for the Commercialization of the applicable Sumitomo Development Item and applicable
    Zymergen Development Item which may include the following terms: (a) Sumitomo’s exclusive right to Commercialize the applicable Sumitomo Development Item incorporating the applicable Zymergen Development Item in the applicable Field (subject to
    profit-sharing with Zymergen in accordance with Section 7.1); (b) each Party’s non-exclusive right to Commercialize the applicable Sumitomo Development Item and applicable Zymergen Development Item incorporated to such Sumitomo Development
    Item, in each case, outside the Field; (c) the exclusive supply of the applicable Zymergen Development ltem(s) by Zymergen to Sumitomo for incorporation to the applicable Sumitomo Development Item(s) within or outside the Field; (d) licenses to
    Sumitomo Background Technology and Zymergen Background Technology necessary to commercially exploit the applicable Sumitomo Development Item(s) and Zymergen Development Item(s) within or outside the Field; and (e) any standard and customary provisions
    applicable to a transaction of this nature.

   

  6.5           Deliverables and Related Information. Neither Party shall use either the Sumitomo Development items, Zymergen Development items or Deliverables, including, in each case, any related information, for
    any purpose other than as expressly permitted in this Agreement

   

  

  
    6 

    
      
 

  

   

  Zymergen - Sumitomo Strategic Partnership Agreement

   

  and shall not transfer any of the foregoing to any Affiliate or Third Party other than as expressly permitted in this Agreement.

   

  6.6           Reserved Rights, Each
    Party acknowledges that the rights and licenses under this Article 6 are limited to the express scope thereof. Accordingly, except for the rights and licenses expressly granted under this Agreement, no right, title, or interest of any nature
    whatsoever is granted, whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party. Except to the extent specifically granted herein, each Party reserves all right title and interest in and to the Background Technology,
    Know-how and Intellectual Property Rights of such Party.

   

  6.7           Patent Filings.

   

  6.7.1        General; Cooperation.
    The Party primarily contributing to the [***] shall be the prosecuting Party for such [***] and shall bear the costs related to prosecution and filing; provided however, the annuity and maintenance fees related to [***] shall be shared equally
    by the Parties. The prosecuting Party for the [***] shall consult with designees of the other Party on all matters concerning the preparation, filing, countries of filing, prosecution, and maintenance of all patent applications, amendments, and other
    documents relating to [***], including the selection of patent counsel to handle any patent matter concerning [***]. The prosecuting Party shall consider all information the other Party may provide concerning [***] and implement all reasonable written
    requests by the other Party concerning the preparation, filing, prosecution, or maintenance of [***] patent applications, patents, or other Intellectual Property Rights applications or registrations.

   

  6.7.2       Joint Research Agreement. This Agreement is intended to and hereby does serve, among other things, as a “joint research agreement” for purposes of Section 102(e) of the US
    Patent Act (Patent Act), 35 U.S.C. § 102(c). Each Party shall provide the other Party with all reasonable assistance and cooperation, including the preparation and filing of any terminal, or statutory, disclaimers and other documents, required to
    procure and preserve the protections under the Patent Act for all Foreground IP.

   

  6.7.3       Forfeiture of Rights in [***]. Either Party may forfeit its rights to applicable [***] related to a specific Project Plan upon thirty (30) days written notice to the other
    Party. Upon the date of forfeiture, the forfeiting Party shall (a) have no rights in such [***], (b) have no obligation to pay annuity and maintenance fees incurred after the forfeiture date, (c) except as set forth in subsection (b) of this Section

      6.7.3, remain responsible for its obligations under the applicable terms of this Agreement and (d) upon request of the non-forfeiting Party within such thirty (30) day written notice period, assign the [***] to the non-forfeiting Party.

   

  6.7.4        No Representation or Waiver of
        Privilege, For clarity, each Party’s patent attorneys and patent agents represent such Party, and no interaction between a Party and any patent attorney or patent agent representing the other Party pursuant to this Section 6.7
    shall create any attorney-client relationship between such Party and such attorney or agent. The Parties understand and agree that any cooperation with respect to the filing, prosecution and maintenance of any patents or patent applications described
    in this Section 6.7 shall not act as a

   

  
    7 

    
      
 

  

   

  

  Zymergen - Sumitomo Strategic Partnership Agreement

   

  waiver of any privilege, and the Parties will cooperate to take any actions that the Parties determine to be necessary or reasonably desirable to
    preserve such privilege.

   

  6.8           Enforcement of [***].

   

  6.8.1         Infringement of [***]. A Party receiving notice of an alleged infringement of any [***] or is a Party to a
    declaratory judgment action alleging the invalidity or non-infringement of any [***] patent, shall promptly provide written notice to the other Party of the alleged infringement or declaratory judgment action, as applicable. The Parties’ shall mutually
    determine a response and course of action, including the commencement of any suit or other proceeding to enjoin, prohibit, or otherwise secure the cessation of such infringement or to defend against declaratory relief actions. Subject to Section 6.8.2,
    if the Parties decide to proceed with any such suit or other proceeding, the Parties shall: (i) jointly select litigation counsel to prosecute the suit to maximize revenue from and create the best market environment for the development item(s); (ii)
    jointly select the forum for the suit and each join the suit as a party to perfect or maintain jurisdiction to continue the suit in such forum; (iii) cooperate with each other, including giving testimony and producing documents lawfully requested in
    the course of the suit or other proceeding and cause its, and its Affiliates’, Representatives to cooperate with the other Party; (iv) share, in accordance with the applicable profit share, all out-of-pocket costs and expenses, including reasonable
    attorneys’ and experts’ fees, incurred in commencing and maintaining such suit; and (v) each have the right to receive payment equal to such Party’s applicable profit share of the balance of any settlement amount, damages, or other monetary awards
    recovered in connection with the suit or proceeding that remains after reimbursement of their respective actual out-of-pocket costs and expenses paid pursuant to this Section 6.8.1; provided that, if the settlement or damage award amount does
    not fully reimburse the Parties’ aggregate out-of-pocket litigation costs and expenses, the settlement or damage award amount shall be shared pro-rata based on each Party’s applicable profit share,

   

  6.8.2        Election Not to Proceed, If one of the Parties elects not to proceed with a suit or other proceeding as recommended by the other Party pursuant to Section 6.8.1, the other Party may, but is not
    obligated to, commence and maintain such suit or other proceeding at its own cost and expense. If that Party elects to proceed with the suit or other proceeding, the Party electing to proceed shall have the exclusive right to: (a) select and retain
    litigation counsel of its choosing; and (b) direct and control such suit or other proceeding and receive and retain all settlement amounts, damages, and other monetary awards recovered in connection with it. A party initiating or defending any suit or
    proceeding pursuant to this Section 6,8.2 shall have the exclusive right, in its sole discretion, to settle and compromise such suit or proceeding, whether by settlement or other voluntary final disposition, without the prior written approval
    of the other Party, provided that the terms of such resolution do not: (i) enjoin any future action by the other Party or any of its Affiliates, licensees, sublicensees, or customers (including the other party, “Affected Persons”); (ii) derogate from or diminish any of the other Party’s rights or licenses under this Agreement; (iii) require any of the Affected Persons to make any payment; (iv)   fail to grant the other Party and its Affiliates a release of all claims in the suit or proceeding; (v)   require the
    admission or concession that any claim or aspect of any Foreground IP is invalid or unenforceable, or require any waiver or disclaimer of any rights with respect to such claim or patent; or (vi) otherwise have a material adverse effect upon any of the
    Affected Persons, any of their assets, or any objectives or subject matter of this Agreement. 

   

  
    8 

    
      
 

  

   

  

  Zymergen - Sumitomo Strategic Partnership Agreement

    

  7.             Costs; Profit Sharing; Right to Supply.

   

  7,1          Costs and Profit Sharing. Costs will be set forth in the specific Project Plan. All direct out-of-pocket costs described in the
    applicable Project Plan or approved by the JSC and (b) Net Profits related to Commercialization in the Field of the applicable Sumitomo Development Item(s) and applicable Zymergen Development Item(s) shall be [***] by the Parties, to be [***]; provided,
    however, the Parties [***] (e.g., [***]), if agreed to in the applicable Project Plan. Except as set forth in a Project Plan, Sumitomo and Zymergen shall each be responsible for its own costs and expenses pursuant to this Agreement. For purposes
    of this Section 7.1, “Net Profits” means the profit of a company after operating expenses and all other charges including taxes, interest and depreciation have been deducted from
    total revenue.

   

  7.2          Right to Supply.
    Upon the conclusion of a particular Project Plan, the Parties shall discuss the Commercialization prospects for the resulting Sumitomo Development Item(s) and, in turn, the supply of related Zymergen Development Items. Such discussion shall include
    agreements by the Parties concerning target pricing for the Sumitomo Development ltem(s) (or end products incorporating the Sumitomo Development Item(s)) and assessments of the respective costs of production at commercial scale for the Sumitomo
    Development Item(s) or end products and the Zymergen Development Item(s). The Parties hereby agree that Zymergen shall have the exclusive right to supply the Zymergen Development Item(s) to Sumitomo in view of the agreements and assessments mentioned
    in the preceding sentence. If, at any time, Sumitomo desires to obtain supply of a Zymergen Development Item, Sumitomo shall notify Zymergen in writing (the “Offer
          Notice”) of the material financial and other terms and conditions in which Sumitomo desires to enter into agreement with Zymergen for the supply of the applicable Zymergen Development Item (the “Material Terms”). Each Offer Notice constitutes an offer made by Sumitomo to enter into an agreement with Zymergen on the Material Terms (the “Supply Offer”). At any time prior to the expiration of the thirty (30) day period following Zymergen’s receipt of the Offer Notice (the “Exercise Period'”), Zymergen may accept the Supply Offer by delivery to Sumitomo of a binding letter of intent containing the Material Terms and any standard and customary conditions
    applicable to a transaction of this nature, executed by Zymergen. If, by the expiration of the Exercise Period, Zymergen has not accepted the Supply Offer, and provided that Sumitomo has complied with all of the provisions of this Section
      7.2, Sumitomo may (a) at any time during the [***] ([***]) day period following the [***], enter into [***] to toll [***] Zymergen Development ltem(s) for the [***] on Material Terms that are the same [***] as the Material Terms or (b) within the
    time period tor first supply, as defined in the Offer Notice, [***] for the supply of the applicable Zymergen Development ltem(s) with costs (calculated using [***] on any [***]) that are the same [***] as the Material Terms (a “[***]”). Regardless, if Sumitomo does not consummate [***] period or build [***] in the time period set forth in the Offer Notice, as applicable, the terms and conditions of [***] will
    again apply and Sumitomo [***] without affording Zymergen [***] of this Section 7.2. For the avoidance of doubt, the terms and conditions of this Section 7.2 apply each time Sumitomo desires to enter into [***]. 

   

  
    9 

    
      
 

  

   

  

  

  Zymergen - Sumitomo Strategic Partnership Agreement

    

  [***] including increasing in [***]. [***] for purposes of this Section 7.2 means all direct costs associated with manufacturing

      and delivering the Zymergen Development Item to a similar location as specified in the Material Terms. For the avoidance of doubt, [***] Sumitomo and Zymergen
      entering into a supply arrangement for a given Zymergen Development Item hereunder.

   

  7.3          Audit Rights.
      On twenty (20) business days’ notice and during regular business hours, either Party may, through the use of a Third Party auditor and at its own expense, reasonably audit the other Party’s books, records, and other documents as necessary to
    verify compliance with the terms and conditions of this Article 7 and any other payment or cost-sharing obligations contained in a Project Plan.

   

  8.            Confidential Information.

   

  8.1           Confidential Obligations. During the term of this Agreement and for a period of ten (10) years after expiration or termination of this Agreement, the Parties agree that the Party to whom
    Confidential Information is disclosed hereunder (the “Receiving Party”) shall not, other than in the performance of its obligations or exercise its
    rights under this Agreement and except as expressly provided in this Article 8, (a) disclose to any Third Party, or (b) use for any purpose, any Confidential Information furnished to it by the other Party (the “Disclosing Party”). Additionally, each Receiving Party shall maintain the Disclosing Party’s Confidential Information in confidence using at least the same degree of care that the
    Receiving Party uses for its own Confidential Information, but in no event using less than reasonable care. Each Party hereby represents that all of its employees, directors, agents and consultants, and all of the employees, directors, agents and
    consultants of its Affiliates, who have or may have access to the Confidential Information of the other Party are, or will prior to having such access be, bound by written obligations of confidentiality and non-use at least as strict those as described
    in this Article 8. Each Party shall, and shall cause its Affiliates to, cnforce such obligations and prohibit its employees, directors, agents and consultants from using the Confidential Information of the other Party except as expressly
    permitted hereunder. Each Receiving Party will be liable to the other for any prohibited disclosure or misuse by its employees, directors, agents or consultants of Confidential Information of the Disclosing Party.

   

  8.2           Exceptions. The obligations of confidentiality and limited use set forth in Section 8.1 shall not apply to any Confidential Information of the other Party that: (a) was already in the
    public domain, e.g., is publicly available by publication or other documented means, at the time of disclosure to the Receiving Party; (b) becomes part of the public domain after disclosure to the Receiving Party, e.g., become publicly available by publication or other documented means, through no fault of the Receiving Party; (c) was already known to Receiving Party before disclosure from the Disclosing Party, as
    demonstrated by the Receiving Party’s contemporaneous written records; (d) is made known to Receiving Party by a Third Party lawfully in possession thereof and who has the lawful power to disclose such information to the Receiving Party without any
    restriction imposed by or obligation to the Disclosing Party; or (e) is independently developed by the Receiving Party as evidenced by credible written research records of Receiving Party’s employees or agents who did not use, access or reference the
    Disclosing Party’s Confidential Information. For the avoidance of doubt, any specific information shall not be deemed to be within

   

  

  
    10 

    
      
 

  

   

  

  

  Zymergen - Sumitomo Strategic Partnership Agreement

    

  any of these exclusions merely because it is embraced by more general information falling within these exclusions.

   

  8.3           Permitted Disclosures. Notwithstanding the obligations in Section 8.1, the Receiving Party may disclose the Confidential Information of the Disclosing Party to: (a) those of the Receiving Party’s officers, directors, employees, agents or contractors to
    whom disclosure is necessary to enable such persons to perform the Receiving Party’s obligations under this Agreement; (b) persons to whom such Confidential Information must be disclosed in connection with an order of a court or legal compulsion to a
    government body or as otherwise required by or in compliance with law or regulations; provided that the Receiving Party that is being compelled to disclose such Confidential Information provides the other Party with prompt notice and
    takes reasonable steps to restrict further disclosure by said court or authorities and the affected Confidential Information so disclosed is not otherwise removed from the secrecy obligation; (c) relevant authorities for the sole purposes of obtaining
    governmental approvals; provided that the Receiving Party uses commercially reasonable efforts to preserve the confidentiality of such Confidential Information; (d) the Receiving Party’s directors, attorneys, independent accountants or
    financial advisors to whom disclosure is necessary to enable such persons to provide advice to the Receiving Party; or (e) the Receiving Party’s actual or potential investors, investment bankers, acquirors, licensees and other financial or commercial
    partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition or collaboration. Provided that in the cases of (a), (d) and (e), such recipients are provided only such Confidential Information as may be
    required by the specific basis for disclosure in each instance, and are bound by confidentiality and non-use obligations substantially consistent with those contained in this Agreement, except that the duration of such obligations for recipients in (e)
    may be shorter than the duration in this Agreement as long as it is at least three (3) years from the date of disclosure.

   

  8.4           Marking. Without limiting the definition of Confidential Information, each Disclosing Party agrees to use reasonable efforts to mark any Confidential Information as “confidential” or “proprietary”
    (whether by letter or by the use of an appropriate stamp or legend) prior to or at the time of such disclosure, and (b) with respect to Confidential Information disclosed in a form other than in writing, (!) to promptly reduce such disclosure of
    Confidential information to writing, (ii) mark such written reduction as “confidential” or “proprietary,” and (iii) provide such reduction to writing to the other Party within thirty (30) days of such other disclosure).

   

  8.5           Return of Confidential Information. Upon written request by the Disclosing Party, the Receiving Party will promptly return or destroy all Confidential Information of the Disclosing Party, including
    any documents prepared by the Receiving Party that contain Confidential Information of the Disclosing Party, except those documents that the Receiving Party must retain as specified in this Agreement or to fulfill regulatory requirements. However, the
    Receiving Party may retain, in a secure location and, to the extent possible, segregated from unrelated materials, a single archival copy of returned Confidential Information for the sole purpose of determining the scope of obligations incurred under
    this Agreement, accessible solely by the attorneys of the Receiving Party specifically responsible for monitoring such compliance. Notwithstanding anything to the contrary, if the Receiving Party retains an archival copy of returned Confidential
    Information of the Disclosing Party, the obligations of confidentiality as to the archival copy shall continue for so long as the archival copy is maintained and the information constitutes Confidential Information.

   

  

  
    11 

    
      
 

  

   

  Zymergen - Sumitomo
        Strategic Partnership Agreement

   

  8.6           Relief. The
    Parties acknowledge and agree that a breach of the provisions of this Article 8 of this Agreement may cause the Disclosing Party to suffer irreparable damage that could not be adequately remedied by an action at law. Accordingly, the receiving
    Party agrees that the disclosing Party shall have the right to seek specific performance of the provisions of this Article 8 to enjoin a breach or attempted breach of the provisions thereof, such right being in addition to all other rights and
    remedies available to the Disclosing Party at law, in equity, or otherwise,

   

  8.7           Terms of this Agreement.
    Each Party agrees to treat the terms of this Agreement as the Confidential Information of the other Party. A Party may disclose this Agreement and its terms in accordance with Section 8.3 and in securities filings with the Securities Exchange
    Commission (or equivalent foreign agency) to the extent required by applicable law after complying with the procedure set forth in this Section 8.7. In such event, the Party seeking such disclosure shall use commercially reasonable efforts to
    obtain confidential treatment of this Agreement from the Securities Exchange Commission (or equivalent foreign agency). The Party seeking such disclosure shall provide the other Party with a proposed redacted version of this Agreement for confidential
    treatment request, and the other Party agrees to promptly (and in any event, no less than seven (7) days after receipt of such proposed redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request
    within the time lines proscribed by applicable law. The Party seeking such disclosure shall consider in good faith the comments provided by the other Party.

   

  8.8           Publicity. The

    Parties will issue a joint publication regarding their relationship under this Agreement through a press release and other standard market communication tools as mutually agreed. Except as set forth herein and to the extent required by law, neither
    Party will use the name or corporate logo of the other Party without that other Party’s prior written consent and any other conditions attached to such consent.

   

  		9.	Term and Termination.

   

  9.1           Term. This
    Agreement shall commence on the Effective Date and shall continue for six (6) years, and shall automatically extend for additional one (1) year periods (collectively, the “Term”), unless either
    Party provides the other with written notice of its intent not to extend the term no less than one hundred eighty (180) days prior to the end of the then-current term.

   

  9.2           Termination for Material
        Breach. If a Party has committed a material breach of any obligation under this Agreement, the other Party may terminate this Agreement, in its entirety or on a Project Plan-by-Project Plan basis (as described below) if the defaulting
    Party does not cure the breach (where the breach is capable of cure) within sixty (60) days from the date of the terminating Party’s notice of such breach. If the uncured material breach is of an obligation pursuant to a particular Project Plan and
    occurs during the Development Term for such Project Plan, then the termination shall apply solely with respect to the applicable Project Plan. If the uncured material breach is of an obligation under this Agreement that does not pertain to any
    particular Project Plan, then this Agreement shall terminate in its entirety. The applicable termination shall become immediately effective at the end of the applicable cure period.

   

  9.3           Termination for
        Insolvency. Either Party may terminate this Agreement upon written notice to the other Party if, at any time: (a) the other Party makes an assignment for the

   

  
    12 

    
      
 

  

   

  

  Zymergen - Sumitomo
        Strategic Partnership Agreement

  

   

  benefit of creditors or admits in writing its
      inability generally to pay or is generally not paying its debts as such debts become due; (b) any decree or order for relief is entered against the other Party under any bankruptcy, reorganization, compromise, arrangement, insolvency, readjustment of
      debt, dissolution or liquidation or similar law; (c) the other Party petitions or applies to any tribunal for, or consents to, the appointment of, or taking possession by, a trustee, receiver, custodian, liquidator or similar official, of such Party
      or any substantial part of its assets, or commences a voluntary case under the bankruptcy law of any jurisdiction; (d) any such petition or application is filed, or any such proceedings are commenced, against the other Party and such Party by any act
      indicates its approval thereof, consent thereto or acquiescence therein, or an order, judgment or decree is entered appointing any such trustee, receiver, custodian, liquidator or similar official, or approving the petition in any such proceedings,
      and such order for relief, order, judgment or decree remains unstayed and in effect for more than sixty (60) days; or (e) any order, judgment or decree is entered in any proceedings against the other Party decreeing the dissolution of such Party and
      such order, judgment or decree remains unstayed and in effect for more than sixty (60) days.

   

  9.4           Mutual Termination.
    The Parties may terminate this Agreement and all Project Plans hereunder at any time by written agreement.

   

  9.5           Effects of Termination.
    Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Without limiting the foregoing, Articles 1, 5, 6, 8, 9, 11, 12
    and 13 and Sections 2.3, 7.1, 7.2 (until the last to expire of any patents directed to [***]), 7.3 and 10.2 will survive expiration or earlier termination of this Agreement. Expiration or termination of
    this Agreement shall also terminate all Project Plans.

   

  9.6           Termination Not Sole
        Remedy. Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, alt other remedies shall remain available except as
    agreed to otherwise herein. Without limiting the foregoing, termination of this Agreement or any Project Plan hereunder is without prejudice to (a) the rights of each Party to sue for and recover any fees or amounts then due and (b) the rights of each
    Party in respect of any previous breach of any of the provisions of this Agreement.

   

  		10.	Representations, Warranties and Covenants

   

  		10.1	Mutual Representations, Warranties and Covenants.

   

  10.1.1 Power, Authority and Conflicts.
    Each Party represents and warrants, as of the Effective Date, that: (a) it is authorized to enter into this Agreement and it is not aware of any claim, matter or thing, which
      would stop it from granting the rights or performing its obligations as provided for in this Agreement; (b) the execution and delivery of this Agreement constitutes a legal, valid, and binding obligation of such Party enforceable against it in
      accordance with its terms and conditions; and (c) the performance by it of the transactions contemplated hereby, to its knowledge, does not violate and will not violate: (i) in any material respect, any agreement, instrument, or contractual
      obligation to which such Party is bound; (ii) any requirement of any applicable law or regulation; or (iii) any order, writ, judgment, injunction,

   

  
    13 

    
      
 

  

   

  Zymergen - Sumitomo
        Strategic Partnership Agreement

   

  decree, determination, or award of
      any court or governmental authority presently in effect applicable to such Party.

   

  10.1.2     Compliance with Law.
      Each Party represents and warrants and covenants to the other Party that it shall fully observe and comply with all applicable national, state and local laws, rules, regulations and orders pertaining to its activities under this Agreement.

   

  10.1.3     Export Compliance.
      Each Party represents and warrants and covenants to the other Party that it shall not knowingly export, directly or indirectly, in connection with performance of its obligations or exercise of its rights under this Agreement, any United States source
      technical data acquired from a United States based company, or any direct product of that technical data, to any country for which the United States government or any agency thereof at the time of export requires an export license or other approval,
      without first obtaining such license or approval, when required by applicable United States or other national law. The Parties agree that the transfer of technology and technical information may be export controlled by the United States government
      and the Parties are subject to such export control laws. Therefore, each Party represents and warrants and covenants to the other Party that is shall not provide any technology or technical information shared between the Parties to any country or
      citizens of a country identified by the United States’ or other national authorities as either an embargoed or sanctioned country to which such provision of information is prohibited.

   

  10.1.4    Anti-Bribery.
      Each Party represents and warrants and covenants to the other Party, that at all times while performing services, such Party shall comply with the requirements of the U.S. Foreign Corrupt Practices Act and all other applicable anti-bribery and
      anti-corruption laws of the jurisdictions where the services are being performed.

   

  10.2   
        Warranty Disclaimer. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 10, (A) NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER
      EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, AND ANYTHING PROVIDED BY ONE PARTY TO THE OTHER PURSUANT TO THIS AGREEMENT IS PROVIDED “AS IS,” AND (B) EACH PARTY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND OR NATURE, WHETHER EXPRESS OR IMPLIED,
      RELATING TO THE SUBJECT MATTER HEREUNDER, INCLUDING ANY WARRANTIES OF MERCHANTABILITY, TITLE, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. EACH PARTY ACKNOWLEDGES THE UNCERTAINTIES OF RESEARCH AND DEVELOPMENT ACTIVITIES AND ACCEPTS THAT
      THERE IS NO GUARANTEE THAT ANY DESIRED OUTCOME WILL BE ACHIEVED THROUGH THE CARRYING OUT OF ANY PROJECT PLAN PURSUANT TO THIS AGREEMENT.

   

  		11.	Dispute Resolution, Governing Law, and Venue.

   

  11.1         
        Initial Escalation. If any dispute arises between the Parties out of or relating to this Agreement (a “Dispute”)
      and such dispute is not resolved after thirty (30) days of good-faith negotiations by the Joint Steering Committee, any Party seeking to resolve such Dispute must notify the other Party of the existence and nature of the Dispute (the “Notification”). Upon receipt

   

  
    14 

    
      
 

  

   

  Zymergen - Sumitomo
        Strategic Partnership Agreement

   

  of the Notification, the Parties shall refer
      the Dispute to their respective Chief Executive Officers or their nominees for resolution.

   

  11.2          Resolution by Arbitration. If the Parties fail to resolve the Dispute within (90) days of the Notification, then the Dispute shall be submitted to arbitration in accordance with Section 11.3.

   

  11.3         Governing Law; Jurisdiction. The formation, existence, performance, validity and all aspects of this Agreement shall be governed by and construed in all respects in accordance with the laws of the State
      of New York, U.S. without regard to its rules on conflicts of laws. The arbitration shall be held in New York in accordance with the Rules of Arbitration of the International Chamber of Commerce (“ICC”). The arbitration panel shall consist of one
      arbitrator appointed by the ICC in accordance with the ICC rules. The arbitration shall be conducted in the English language. The award rendered by the arbitration shall be binding and shall have full legal effect upon the parties.

   

  11.4         Interim Relief. Nothing in this Article 11 will prevent a Party from seeking urgent interlocutory relief through courts of appropriate jurisdiction.

   

  		12.	Indemnification and Limitation on Liability.

   

  12.1         Indemnification. Each Party shall indemnify, defend, and hold harmless the other Party and Affiliates and their respective officers, directors, employees and agents (the “Indemnitees”) against any and all losses, damages, liabilities, expenses and costs, including reasonable legal expense and attorneys’ fees (collectively "Losses")
      arising out of or resulting from any Third Party claim, suit, action, or proceeding (each a "Third Party Claim") arising solely from (a) the Party’s material breach of its representations,
      warranties or covenants under this Agreement, or (b) the fraud, negligence or willful misconduct of any Indemnitee of the other Party in connection with this Agreement.

   

  12.2          Conditions of Indemnification. Each Party’s agreement to indemnify, defend and hold harmless the other Party and its Affiliates, and its and their respective directors, officers, employees and agents
      (collectively, the “Indemnified Party”) is conditioned on the Indemnified Party, (a) providing written notice to the other Party (the “Indemnifying
            Party”) of any Third Party Claim for which it is seeking indemnification hereunder promptly after the Indemnified Party has knowledge of such claim; (b) permitting the Indemnifying Party to assume full responsibility to
      investigate, prepare for and defend against any such claim or demand; (c) assisting the Indemnifying Party, at the Indemnifying Party’s reasonable expense, in the investigation of, preparation for and defense of any such claim or demand; and (d) not
      compromising or settling such claim or demand without the Indemnifying Party’s written consent, not to be unreasonably withheld.

   

  12.3         Waiver of Consequential Damages. NEITHER PARTY WILL BE LIABLE TO THE OTHER FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, MULTIPLE OR OTHER SIMILAR DAMAGES (INCLUDING ANY CLAIMS FOR
      LOST PROFITS OR REVENUES) ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH

   

  
    15 

    
      
 

  

   

  

  Zymergen - Sumitomo
        Strategic Partnership Agreement

   

  DAMAGES. NOTWITHSTANDING THE
      FOREGOING, NOTHING IN THIS SECTION 12.3 IS INTENDED TO OR SHALL LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 12.1, OR (B) DAMAGES AVAILABLE FOR A PARTY’s BREACH OF ARTICLE 8.

   

  		13.	Miscellaneous.

   

  13.1          Entire Agreement. This Agreement (along with all adopted Project Plans and exhibits hereto) constitutes the entire agreement between the Parties and supersedes all communications, negotiations,
      arrangements and agreements, either oral or written, between the Parties, including without limitation the 1st MOU and the 2nd MOU, with respect to the subject matter of this Agreement; provided, however, that, for clarity any confidential information exchanged between the Parties prior to the Effective Date
      including, without limitation, pursuant to that certain Confidentiality Agreement, shall be treated as Confidential Information hereunder; provided further that such Confidentiality Agreement shall remain in force and shall govern with
      respect to any communications outside of the scope of this Agreement. In the event that there is a conflict in the terms and conditions between this Agreement and the Confidentiaiity Agreement, this Agreement shall control,

   

  13.2         Amendments. No agreement or understanding purporting to amend or extend this Agreement shall be legally binding upon the Parties unless it is in writing and signed by duly authorized officers of the
      Parties.

   

  13.3         Waiver. A waiver by a Party of any rights arising from a breach or non-observance by the other Party of a term of this Agreement shall not be taken to operate in any way as a waiver of any rights arising
      from any subsequent continuation of that breach or non-observance, or any further or other breach or non-observance of the same or any other term.

   

  13.4         Severability. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision which shall remain in full force and effect,

   

  13.5         Subcontracting. Each Party may subcontract any of its obligations under this Agreement to a Third Party (“Subcontractor”) without the other
      Party’s consent; provided that Subcontractor has under written confidentiality obligations that are at least as restrictive as those contained in this Agreement.

   

  13.6         Assignment. Neither Party may assign this Agreement without first obtaining the prior written consent of the other Party; provided, however, that (a) either Party may assign this
      Agreement and all of its rights and obligations hereunder, without such consent, to a person that acquires all or majority of the shares or assets of such Party (or the business or assets to which this Agreement pertains) whether by merger,
      consolidation, reorganization, acquisition, sale, license or otherwise, and (b) each Party may assign this Agreement and all of its rights and obligations hereunder, without such consent, to an Affiliate, so long as the assigning Party remains liable
      and responsible for the performance and observance of any obligations so assigned. Any assignment not in accordance with this Section 13.6 shall be void. Upon assignment, all the rights and

   

  
    16 

    
      
 

  

   

  Zymergen - Sumitomo
        Strategic Partnership Agreement

   

  obligations under this Agreement shall be
      binding upon and inure to the benefit of any successor or permitted assign.

   

  13.7         Notice. Any notice under this Agreement must be in a writing to the applicable address and recipients set out below (unless the relevant Party notifies the other Party of another address to which notices
      or communications are to be sent). Each Party shall provide a courtesy copy of any notice hereunder by email.

   

  	To Sumitomo:	Sumitomo Chemical Co., Ltd.

  Address: 27-1, Shinkawa 2-chome,
      Chuo-ku, Tokyo 104-8260, Japan

   

  with a copy to:

   

  Sumitomo Chemical Co., Ltd.

  Address: 27-1, Shinkawa 2-chome,
      Chuo-ku, Tokyo 104-8260, Japan

  [***]

   

  	To Zymergen:	
          Zymergen Inc.

          Attn:

        

  5980 Horton St, Suite, 105

  Emeryville CA 94608

  elephone:

  mail:

   

  with a copy to;

   

  Zymergen Inc.

  Attn: Office of the General Counsel

  5980 Horton St, Suite 105

  Emeryville CA 94608

  Email: legaInotices@zymergen.com

   

  13.8          Effectiveness of Notice Letter or Electronic Mail. Notice provided by letter or electronic mail provided in accordance with Section 13.7 shall be deemed received as follows: (a) in the case of a
      certified letter, on the third (3rd) day after posting; (b) in the case of delivery by next day courier (such as FedEx or UPS next day services), on the next business day after deposit with the next day courier; (c) in the case of email sent during
      ordinary business hours in the recipient’s location on a business day in recipient’s location, on the day on which the email is sent; or (d) in the case of email sent outside ordinary business hours in the recipient’s location on a business day or on
      a day which is not a business day in the recipient’s location, on the next business day after the email is sent.

   

  13.9          Waiver of Formal Notice, A notice sent by means other than certified letter, next day courier, or facsimile shall not be considered effective, unless the receiving Party clearly and

   

  
    17 

    
      
 

  

   

  Zymergen - Sumitomo
        Strategic Partnership Agreement

   

  expressly (a) waives the notice
      requirements for that specific notice and (b) acknowledges receiving that specific notice in a writing.

   

  13.10       Joint Drafting. Each Party participated in drafting this Agreement and each Party acknowledges having ample opportunity to (a) review and influence the terms of this Agreement and (b) consult an attorney
      and obtain legal counsel regarding this Agreement.

   

  13.11        Relationship of the Parties. It is expressly agreed that the Parties shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or
      agency. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.

   

  13.12        Force Majeure. Where a Party is (a) unable, wholly or in part, to carry out any obligation under this Agreement by reason of any Force Majeure and (b) that affected Party:

  (i)   gives the other Party prompt notice
      of that Force Majeure, including reasonable particulars; and (ii)   uses all reasonable diligence to remove or mitigate the circumstances caused by that Force Majeure as quickly as possible, then the affected Party shall not be in breach of the
      obligation effected by Force Majeure during the continuance of that Force Majeure; provided that if the Force Majeure continues for a period of three (3) months, then Parties shall meet in good faith to achieve a satisfactory resolution to
      the problem. For clarity, the requirement that any Force Majeure set forth in Section 13.12(b)(ii) must be removed with all reasonable diligence does not require the settlement of strikes, lockouts or other labor disputes or claims or demands
      by any government on terms contrary to the wishes of the Party affected.

   

  13.13       Further Assurances. Each Party must exccutc such agreements, deeds and documents and do or cause to be executed or done all such acts and things as are necessary to give effect to the provisions of this
      Agreement including execution of all documents required to assign, sublicense, or license any Intellectual Property Rights and/or to obtain regulatory authority approval in accordance with the express terms of this Agreement.

   

  13.14      Counterparts. This Agreement may be executed in counterparts, each of which shall be an original as against either Party whose signature appears thereon, but all of which taken together shall constitute
      but one and the same instrument. An executed facsimile or electronic scanned copy of this Agreement shall have the same force and effect as an original,

   

  [Signature Page Follows]

   

  
    18 

    
      
 

  

   

  In Witness Whereof, the Parties have caused this Strategic Partnership
        Agreement to be executed by their respective authorized representatives, effective as of the Effective Date.

   

  		Zymergen Inc.
	 	 

  	 	By:	/s/ Richard Pieters
	 	Name:	Richard Pieters
	 	Title:	President

   

  

  		Sumitomo
              Chemical Co. Ltd
	 	 

  

  

  	 	By:	[***]
	 	Name:	[***]
	 	Title:	[***]

    

    Signature Page to Strategic Partnership Agreement

   

  
     

    
      
 

  

   

  Exhibit A

   

  AGREEMENT DEFINITIONS

  “1st MOU” has the meaning set forth in the background.

   

  “2nd MOU” has the meaning set forth in the background.

   

  “Affected
          Persons” has the meaning set forth in Section 6.8.2.

   

  “Affiliate” means with respect to a particular Party or third person, any person or entity that directly or indirectly controls, is controlled by, or is in common control with, such Party or
      third person, The term “controls” (with correlative meanings for the terms “controlled by” and "under common control with") means (a) the ownership, directly or indirectly, of fifty (50%) per cent or more of the voting securities or other ownership
      interest of an entity, or (b) the possession, directly or indirectly, of the power to direct the management or policies of the entity, whether through the ownership of voting securities, by contract, or otherwise.

   

  “Application” means the product eategory/ics as defined in the applicable Project Plan.

   

  “Background

          Technology” of a Party means, for each particular Project Plan, the Know- how and Intellectual Property Rights that (a) are Controlled by that Party as of
      the effective date of such Project Plan, or (b) become Controlled by that Party after the effective date of such Project Plan as a result of activities independent of such Project Plan.

   

  “Commercial

          Agreement” has the meaning set forth in Section 6.4.

   

  “Commercialize” means to, directly or through an authorized Third Party or Affiliate, use, make, have made, reproduce, modify, import, sell, produce for sale, offer for sale, commercially license,
      distribute and otherwise commercialize or exploit the applicable Sumitomo Development Item and Zymergen Development Item. The terms “Commercialization” and “Commercializing” shall be similarly construed.

   

  “Confidentiality

          Agreement" means the Mutual Nondisclosure Agreement between the Parties dated May 31, 2017, as amended October 2, 2018 and as may be further amended from
      time to time by the Parties.

   

  “Confidential

          Information” of a Party means all information of such Party, in whatever form, including scientific, technical, financial and business information, that is
      disclosed to or otherwise provided to the other Party pursuant to this Agreement. Confidential Information shall include all information disclosed under the Confidentiality Agreement that was considered "Proprietary Information" thereunder and all
      information exchanged by the Parties in contemplation of entering into any additional Project Plans hereunder.

   

  “Control”
        means, with respect to a Party and any material, Know-how, or Intellectual Property Right, that such Party (a) owns or (b) has a license (other than a license
      granted to such Party under this Agreement) to such material, Know-how, or Intellectual Property Right and, in each case, has the ability to grant to the other Party access, a license, or a sublicense (as applicable)

   

  
     

    
      
 

  

   

  to the foregoing on the terms and conditions set forth in this Agreement
      without violating the terms of any then-existing agreement or other arrangement with any Third Party.

   

  “COR” has the meaning set forth in Section 7.2.

   

  “Development Term” means the term of a Project Plan as identified therein, which term shall begin on the Start Date and shall end after the period of time following the Start Date as specified in the
      Project Plan or, if sooner, the termination of the Project Plan or this Agreement in accordance with the terms of this Agreement or the applicable Project Plan,

   

  “Deliverable” or “Deliverables” means all materials and information arising from a Project Plan that have been or to be provided
      pursuant to this Agreement, and may include either tangible deliverables (e.g., [***]) or technical deliverables (e.g., demonstration of
      achievement

  of production milestones), For each Project Plan, the Deliverables shall
      be set forth in the applicable Project Plan.

   

  “Disclosing Party” has the meaning set forth in Section 8.1.

   

  “Dispute” has the meaning set forth in Section 11.1.

   

  “Exercise Period” has the meaning set forth in Section 1.2.

   

  “Field” means the Application in the Industry, as each is defined in the applicable Project Plan,

   

  “Force Majeure” means in events beyond the reasonable control of the affected Party, including without limitation fire, lightning, explosions, flood, subsidence, earthquake, unusually severe
      weather, insurrection or civil disorder or military operations, acts of government or quasi- government such as government or quasi-government restraint, expropriation, prohibition, intervention, direction or embargo, inability or delay in obtaining
      governmental approvals or quasi-governmental approvals, consents, permits, licenses or authorities, or strikes, lock-outs or other industrial disputes of any kind, in each case to the extent outside of the affected Party’s reasonable control.

   

  “Foreground IP" means any Invention or IPR, other than Sumitomo Background Technology or Zymergen Background Technology, that is conceived, reduced to practice or otherwise generated by employees
      or contractors of either Party during the Development Tenu in the course of conducting activities under any Project Plan hereunder.

   

  “Gene-based Tools” means gene targeting or modification techniques or genetic modifications Controlled by Zymergen that are used to create classically improved and/or genetically modified host cells
      and are capable of being embodied, in whole or in part, in a host. Gene-based Tools (a) may cause beneficial mutations to, or beneficially perturb, genes in a given Host, (b) can include genetic sequences that are not transcribed or that otherwise
      affect transcription and that are selectively mutated or inserted in non-native regions of a host cell’s genome (e.g., Zymergen promoter ladders), and (c) can include gene products not naturally
      produced by a host cell, the coding sequences for which are inserted into a host cell’s genome.

   

  
     

    
      
 

  

   

  "Indemnified Party" has the meaning given in Section 12.2.

   

  "Indemnifying Party" has the meaning given in Section 12.2.

   

  "Indemnitees" has the meaning set forth in Section 12.1.

   

  "Industry" means the industry/ies as defined in the
      applicable Project Plan.

   

  "Intellectual Property Rights"
    or "IPR" means all rights constituted by statute, law or otherwise relating to industrial or intellectual property
      and which include, but are not restricted to, patents, trade secrets, copyrights, designs, trademarks, and all other rights as defined by Article 2 of the Convention establishing the World Intellectual Property Organization of July 1967 and all
      applications relating to these rights.

   

  "Invention" means any process, method, composition, formulation, article of manufacture, method, discovery, Know-How or finding, patentable or otherwise, including all rights, title and interest
      in and to the Intellectual Property Rights therein.

   

  "[***]" has the meaning set forth in Section 6.2.

   

  "Joint Steering Committee" or "JSC" has the meaning given in Section 4.1.1.

   

  "Know-How" means all information, data, results, knowledge, experience or expertise of a technical, commercial, administrative, financial or other nature.

   

  "Losses" has the meaning set forth in Section Error! Reference source not found.

   

  "Material Terms" has the meaning set forth in Section 7.2.

   

  "Net Profits" has the meaning set forth in Section 7.1.

   

  "Notification" has the meaning set forth in Section 11.1.

   

  "Offer Notice" has the meaning set forth in Section 7.2.

   

  "Primary Business" has the meaning set forth in Section 3.3.

   

  "Project Co-Leader" has the meaning set forth in Section 4.2.1.

   

  "Project Plan" has the meaning set forth in Section 2.1.

   

  "Project Proposal" has the meaning set forth in Section 2.1.

   

  "Receiving Party" has the meaning set forth in Section 8.1.

   

  "Representatives" means a party’s and its Affiliates’ employees, officers, directors, consultants, and legal, technical, and business advisors.

   

  
     

    
      
 

  

   

  "Start Date" means the formal beginning of a particular Project Plan, as specified in therein.

   

  "Subcontractor" has the meaning set forth in Section 13,5.

   

  "Sumitomo Background Technology"
    means Background Technology of Sumitomo.

   

  "Sumitomo Development Item(s)"
    means the products to be developed by Sumitomo under a Project Plan in which a Zymergen Development Item is an ingredient or component thereof.

   

  "Sumitomo Plant" has the meaning set forth in Section 7.2.

   

  "Supply Offer” has the meaning set forth in Section 7.2.

   

  "Term" has the meaning set forth in Section 9.1.

   

  "Third Party" means any person or entity that is not a Party to this Agreement or an Affiliate of a Party.

   

  "Third Party Claim" has the meaning set forth in Section Error! Reference source not found..

   

  "Third Party Transaction" has the meaning set forth in Section 7.2.

   

  "Zymergen Background Technology" means (a) Background Technology of Zymergen, including Zymergen 1st MOU IP, (b) Gene-Based Tools,
      and (c) other genome modification techniques and discoveries regarding the functional impact of various genome modifications on strain performance. Zymergen Background Technology expressly excludes Zymergen Platform Tools, in which Zymergen reserves
      all rights, except to the extent that any patent claims owned and controlled by Zymergen relating to Zymergen Platform Tools read on or are embodied in Deliverables or Zymergen Development Items or Sumitomo Development Items.

   

  "Zymergen Development Item(s)"
    means the materials to be developed by Zymergen under a Project Plan.

   

  "Zymergen Platform Tools" means (a) all information, processes, methods, formulations, techniques, algorithms, equipment, models and software that are useful for the creation, modification or improvement of
      strains, including through classical genetics or genetic engineering, (b) all modifications, improvements and enhancements to the foregoing and (c) all Intellectual Property Rights related to any of the foregoing.

   

  
     

    
      
 

  

   

  Exhibit b

   

  PROJECT PLAN TERMS

   

  Each Project Plan in respect of an individual Project Plan shall contain
      the following Sections and subsections:

   

  		●	Project Plan Overview

   

  		●	Section 1 — Project Plan Specific Definitions

   

  		o	"Application" means                

   

  		o	"Development Term" means                    

   

  		o	"Industry" means               

   

  		o	"Industry" means              

   

  		o	"Start Date" means              

   

  		o	"Sumitomo Development Item(s)" means              

   

  		o	"Zymergen Development Item(s)" means                      

   

  		o	[DEFINITIONS RELATED TO SECTIONS BELOW]

   

  		●	Section 2 — Project Management and Governance

   

  		o	Joint Development Committee
	 	 	 

  		o	Project Co-Leaders

   

  		●	Section 3 — Project Phases
	 	 	 

  		o	Phase descriptions and timelines
	 	 	 

  		o	Go / No-Go decision points
	 	 	 

  		o	Obligations and Deliverables (specific regulatory approvals?)
	 	 	 

  		o	Expenses

   

  		●	Section 4 — Development

                Plan

   

  		o	Description of the technical state of the art, technical trends and unmet needs;

   

  		o	Description of the desired Zymergen Development ltem(s) and Sumitomo Development Item(s);

   

  		o	Technical program, including milestones and development cost sharing; and

   

  		o	Timelines

   

  		●	Section 5 — Commercial

                Plan

   

  
     

    
      
 

  

   

  		o	Estimation of market size and business potential in case of successful development;

   

  		o	Value chain break down;

   

  		o	Business Model; and

   

  		o	Value Sharing

   

  		●	Section 6 — Additional Terms Applicable to Project Plan

   

  		o	Intellectual Property Arrangements 

   

  		o	Representations & WarrantiesExhibit 10.4

      

    

     

    

     

    

     

      

      

      

      

      

      

      

      

      

      

      

      

      

      

      

    

     

    

    ZYMERGEN, INC. 

     

      

    2014 STOCK PLAN

     

    

    ADOPTED ON JULY 21, 2014, AS AMENDED

    

       

        

        

        

        

        

        

        

        

        

          

            

          

          

        

        

      

      

    

    
      
        

    

    
    
      TABLE OF CONTENTS

      

      

      

    

    

    

    	 	 	 	
            Page

          
	
            SECTION 1.

          	
            ESTABLISHMENT AND PURPOSE

          	
            1

          
	 	 	 	 
	
            SECTION 2.

          	
            ADMINISTRATION

          	
            1

          
	 	
            (a)

          	
            Committees of the Board of Directors

          	
            1

          
	 	
            (b)

          	
            Authority of the Board of Directors

          	
            1

          
	 	 	 	 
	
            SECTION 3.

          	
            ELIGIBILITY

          	
            1

          
	 	
            (a)

          	
            General Rule

          	
            1

          
	 	
            (b)

          	
            Ten-Percent Stockholders

          	
            1

          
	 	 	 	 
	
            SECTION 4.

          	
            STOCK SUBJECT TO PLAN

          	
            2

          
	 	
            (a)

          	
            Basic Limitation

          	
            2

          
	 	
            (b)

          	
            Additional Shares

          	
            2

          
	 	 	 	 
	
            SECTION 5.

          	
            TERMS AND CONDITIONS OF AWARDS OR SALES

          	
            2

          
	 	
            (a)

          	
            Stock Grant or Purchase Agreement

          	
            2

          
	 	
            (b)

          	
            Duration of Offers and Nontransferability of Rights

          	
            2

          
	 	
            (c)

          	
            Purchase Price

          	
            2

            

          
	 	 	 	 
	
            SECTION 6.

          	
            TERMS AND CONDITIONS OF OPTIONS

          	
            3

          
	 	
            (a)

          	
            Stock Option Agreement

          	
            3

          
	 	
            (b)

          	
            Number of Shares

          	
            3

          
	 	
            (c)

          	
            Exercise Price

          	
            3

          
	 	
            (d)

          	
            Exercisability

          	
            3

          
	 	
            (e)

          	
            Basic Term

          	
            3

          
	 	
            (f)

          	
            Termination of Service (Except by Death)

          	
            4

            

          
	 	
            (g)

          	
            Leaves of Absence

          	
            4

          
	 	
            (h)

          	
            Death of Optionee

          	
            4

          
	 	
            (i)

          	
            Restrictions on Transfer of Options

          	
            5

          
	 	
            (j)

          	
            No Rights as a Stockholder

          	
            5

          
	 	
            (k)

          	
            Modification, Extension and Assumption of Options

          	
            5

          
	 	
            (l)

          	
            Company’s Right to Cancel Certain Options

          	
            5

          
	 	 	 	 
	
            SECTION 7.

          	
            PAYMENT FOR SHARES

          	
            5

          
	 	
            (a)

          	
            General Rule

          	
            5

          
	 	
            (b)

          	
            Services Rendered

          	
            5

          
	 	
            (c)

          	
            Promissory Note

          	
            5

          
	 	
            (d)

          	
            Surrender of Stock

          	
            6

          
	 	
            (e)

          	
            Exercise/Sale

          	
            6

          
	 	
            (f)

          	
            Net Exercise

          	
            6

          
	 	
            (g)

          	
            Other Forms of Payment

          	
            6

          

    

    

    
      i

      
        

    

    	
            SECTION 8.

          	
            ADJUSTMENT OF SHARES

          	
            6

          
	 	
            (a)

          	
            General

          	
            6

          
	 	
            (b)

          	
            Corporate Transactions

          	
            7

          
	 	
            (c)

          	
            Reservation of Rights

          	
            8

          
	 	 	 	 
	
            SECTION 9.

          	
            MISCELLANEOUS PROVISIONS

          	
            8

          
	 	 	 	 
	 	
            (a)

          	
            Securities Law Requirements

          	
            8

          
	 	
            (b)

          	
            No Retention Rights

          	
            8

          
	 	
            (c)

          	
            Treatment as Compensation

          	
            9

          
	 	
            (d)

          	
            Governing Law

          	
            9

          
	 	
            (e)

          	
            Conditions and Restrictions on Shares

          	
            9

          
	 	
            (f)

          	
            Tax Matters

          	
            9

          
	 	 	 	 
	
            SECTION 10.

          	
            DURATION AND AMENDMENTS; STOCKHOLDER APPROVAL

          	
            10

          
	 	
            (a)

          	
            Term of the Plan

          	
            10

          
	 	
            (b)

          	
            Right to Amend or Terminate the Plan

          	
            10

          
	 	
            (c)

          	
            Effect of Amendment or Termination

          	
            10

          
	 	
            (d)

          	
            Stockholder Approval

          	
            10

          
	 	 	 	 
	
            SECTION 11.

          	
            DEFINITIONS

          	
            10

          

    

    

    

    

    
      ii

      
        

      

    

    

    

    

    

    

    

    ZYMERGEN, INC. 2014 STOCK PLAN

    

    

    SECTION 1.             ESTABLISHMENT AND PURPOSE.

    

    

    The purpose of this Plan is to offer persons selected by the Company an opportunity to acquire a proprietary interest in the success of the Company, or to
      increase such interest, by acquiring Shares of the Company’s Stock. The Plan provides both for the direct award or sale of Shares and for the grant of Options to purchase Shares. Options granted under the Plan may be ISOs intended to qualify under
      Code Section 422 or NSOs which are not intended to so qualify.

    

    

    Capitalized terms are defined in Section 11.

    

    

    SECTION 2.              ADMINISTRATION.

    

    

    (a)                Committees of the Board of Directors.   The
      Plan may be administered by one or more Committees.   Each Committee shall consist, as required by applicable law, of one or more members of the Board of Directors who have been appointed by the Board of Directors.   Each Committee shall have such
      authority and be responsible for such functions as the Board of Directors has assigned to it. If no Committee has been appointed, the entire Board of Directors shall administer the Plan. Any reference to the Board of Directors in the Plan shall be
      construed as a reference to the Committee (if any) to whom the Board of Directors has assigned a particular function.

    

    

    (b)                Author ity of the Board of Directors. Subject to the provisions of the Plan, the
      Board of Directors shall have full authority and discretion to take any actions it deems necessary or advisable for the administration of the Plan. Notwithstanding anything to the contrary in the Plan, with respect to the terms and conditions of
      awards granted to Participants outside the United States, the Board of Directors may vary from the provisions of the Plan to the extent it determines it necessary and appropriate to do so; provided that it may not vary from those Plan terms requiring
      stockholder approval pursuant to Section 10(d) below. All decisions, interpretations and other actions of the Board of Directors shall be final and binding on all Purchasers, all Optionees and all persons deriving their rights from a Purchaser or
      Optionee.

    

    

    SECTION 3.             ELIGIBILITY.

    

    

    (a)                General Rule. Only Employees, Outside Directors and Consultants shall be eligible
      for the grant of NSOs or the direct award or sale of Shares 1 Only Employees shall be eligible for the grant of ISOs.

    

    

    (b)                Ten-Percent Stockholders. A person who owns more than 10% of the total combined
      voting power of all classes of outstanding stock of the Company, its Parent or any of its Subsidiaries shall not be eligible for the grant of an ISO unless (i) the Exercise Price is at least 110% of the Fair Market Value of a Share on the Date of
      Grant and (ii) such ISO by its terms is not exercisable after the expiration of five years from the Date of Grant. For purposes of this Subsection (b), in determining stock ownership, the attribution rules of Code Section 424(d) shall be applied.

    

    

    
      
        
          1 Please refer to Exhibit A for a schedule of the initial share reserve and any subsequent increases in the
            reserve.

        

      

      
        

      

    

    
    

    

    SECTION 4.             STOCK

        SUBJECT TO PLAN.

    

    

    (a)                Basic Limitation. Not more than 30,562,701 Shares may be issued under the Plan,
      subject to Subsection (b) below and Section 8(a).2 All of these Shares may be issued upon the exercise of ISOs. The number of Shares that are subject to Options or other
      rights outstanding at any time under the Plan may not exceed the number of Shares that then remain available for issuance under the Plan. The Company, during the term of the Plan, shall at all times reserve and keep available sufficient Shares to
      satisfy the requirements of the Plan. Shares offered under the Plan may be authorized but unissued Shares or treasury Shares.

    

    

    (b)                Additional

      Shares. In the event that Shares previously issued under the Plan are reacquired by the Company, such Shares shall be added to the number of Shares then available for issuance under the Plan. In the event that Shares that otherwise would have been
      issuable under the Plan are withheld by the Company in payment of the Purchase Price, Exercise Price or withholding taxes, such Shares shall remain available for issuance under the Plan. In the event that an outstanding Option or other right for any
      reason expires or is canceled, the Shares allocable to the unexercised portion of such Option or other right shall be added to the number of Shares then available for issuance under the Plan.

    

    

    SECTION 5.             TERMS

        AND CONDITIONS OF AWARDS OR SALES.

    

    

    (a)                Stock Grant or Purchase Agreement. Each award of Shares under the Plan shall be
      evidenced by a Stock Grant Agreement between the Grantee and the Company. Each sale of Shares under the Plan (other than upon exercise of an Option) shall be evidenced by a Stock Purchase Agreement between the Purchaser and the Company. Such award or
      sale shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions which are not inconsistent with the Plan and which the Board of Directors deems appropriate for inclusion in a Stock Grant
      Agreement or Stock Purchase Agreement. The provisions of the various Stock Grant Agreements and Stock Purchase Agreements entered into under the Plan need not be identical.

    

    

    (b)                Duration of Offers and Nontransferability of Rights. Any right to purchase Shares
      under the Plan (other than an Option) shall automatically expire if not exercised by the Purchaser within 30 days (or such other period as may be specified in the Award Agreement) after the grant of such right was communicated to the Purchaser by the
      Company. Such right is not transferable and may be exercised only by the Purchaser to whom such right was granted.

    

     

    

    (c)                Purchase Price. The Board of Directors shall determine the Purchase Price of Shares
      to be offered under the Plan at its sole discretion. The Purchase Price shall be payable in a form described in Section 7.

    

    

    

    

    
      
        
          2 Please refer to Exhibit A for a schedule of the initial share reserve and any subsequent increases in the
            reserve.

        

      

      2

      
        

    

    

    

    SECTION 6.              TERMS AND CONDITIONS OF OPTIONS.

    

    

    (a)                Stock Option Agreement. Each grant of an Option under the Plan shall be evidenced
      by a Stock Option Agreement between the Optionee and the Company.   The Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions that are not inconsistent with the Plan and that
      the Board of Directors deems appropriate for inclusion in a Stock Option Agreement. The provisions of the various Stock Option Agreements entered into under the Plan need not be identical.

    

    

    (b)                Number of Shares. Each Stock Option Agreement shall specify the number of Shares
      that are subject to the Option and shall provide for the adjustment of such number in accordance with Section 8. The Stock Option Agreement shall also specify whether the Option is an ISO or an NSO.

    

    

    (c)                Exercise Price. Each Stock Option Agreement shall specify the Exercise Price. The
      Exercise Price of an Option shall not be less than 100% of the Fair Market Value of a Share on the Date of Grant, and in the case of an ISO a higher percentage may be required by Section 3(b). Subject to the preceding sentence, the Exercise Price
      shall be determined by the Board of Directors at its sole discretion. The Exercise Price shall be payable in a form described in Section 7. This Subsection (c) shall not apply to an Option granted pursuant to an assumption of, or substitution for,
      another option in a manner that complies with Code Section 424(a) (whether or not the Option is an ISO).

    

    

    (d)                Exercisability. Each Stock Option Agreement shall specify the date when all or any
      installment of the Option is to become exercisable. No Option shall be exercisable unless the Optionee (i) has delivered an executed copy of the Stock Option Agreement to the Company or (ii) otherwise agrees to be bound by the terms of the Stock
      Option Agreement. The Board of Directors shall determine the exercisability provisions of the Stock Option Agreement at its sole discretion.

    

    

    (e)                Basic Term. The Stock Option Agreement shall specify the term of the Option. The
      term shall not exceed 10 years from the Date of Grant, and in the case of an ISO, a shorter term may be required by Section 3(b). Subject to the preceding sentence, the Board of Directors at its sole discretion shall determine when an Option is to
      expire.

    

    

    
      3

      
        

    

    (f)                Termination of Service (Except by Death). If an Optionee’s Service terminates for
      any reason other than the Optionee’s death, then the Optionee’s Options shall expire on the earliest of the following dates:

    

    

     (i)          The expiration date determined pursuant to Subsection (e) above;

     

    

    

    (ii)        The date three months after the termination of the Optionee’s
      Service for any reason other than Disability, or such earlier or later date as the Board of Directors may determine (but in no event earlier than 30 days after the termination of the Optionee’s Service); or

    

    

    (iii)       The date six months after the termination of the Optionee’s Service
      by reason of Disability, or such later date as the Board of Directors may determine.

    

    

    The Optionee may exercise all or part of the Optionee’s Options at any time before the expiration of such Options under the preceding sentence, but only to the extent that such
      Options had become exercisable before the Optionee’s Service terminated (or became exercisable as a result of the termination) and the underlying Shares had vested before the Optionee’s Service terminated (or vested as a result of the termination).
      The balance of such Options shall lapse when the Optionee’s Service terminates. In the event that the Optionee dies after the termination of the Optionee’s Service but before the expiration of the Optionee’s Options, all or part of such Options may
      be exercised (prior to expiration) by the executors or administrators of the Optionee’s estate or by any person who has acquired such Options directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that
      such Options had become exercisable before the Optionee’s Service terminated (or became exercisable as a result of the termination) and the underlying Shares had vested before the Optionee’s Service terminated (or vested as a result of the
      termination).

    

    

    (g)                Leaves

      of Absence. For purposes of Subsection (f) above, Service shall be deemed to continue while the Optionee is on a bona fide leave of absence, if such leave was approved by the Company in writing and if continued crediting of Service for this purpose
      is expressly required by the terms of such leave or by applicable law (as determined by the Company).

    

    

    (h)                Death of Optionee. If an Optionee dies while the Optionee is in Service, then the Optionee’s Options
      shall expire on the earlier of the following dates:

    

    

    	

          	(i)	
            The expiration date determined pursuant to Subsection (e) above; or

          

    

    

    (ii)                  The date 12 months after the Optionee’s death, or such earlier or later date as the Board of
      Directors may determine (but in no event earlier than six months after the Optionee’s death). 

    

    

    All or part of the Optionee’s Options may be exercised at any time before the expiration of such Options under the preceding sentence by the executors or administrators of the
      Optionee’s estate or by any person who has acquired such Options directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that such Options had become exercisable before the Optionee’s death (or became
      exercisable as a result of the death) and the underlying Shares had vested before the Optionee’s death (or vested as a result of the Optionee’s death). The balance of such Options shall lapse when the Optionee dies.

    

    

    
      4

      
        

    

    (i)                Restrictions on Transfer of Options. An Option shall be transferable by the
      Optionee only by (i) a beneficiary designation, (ii) a will or (iii) the laws of descent and distribution, except as provided in the next sentence. If the applicable Stock Option Agreement so provides, an NSO shall also be transferable by gift or
      domestic relations order to a Family Member of the Optionee. An ISO may be exercised during the lifetime of the Optionee only by the Optionee or by the Optionee’s guardian or legal representative.

    

    

    (j)                No Rights as a Stockholder . An Optionee, or a transferee of an Optionee, shall
      have no rights as a stockholder with respect to any Shares covered by the Optionee’s Option until such person files a notice of exercise, pays the Exercise Price and satisfies all applicable withholding taxes pursuant to the terms of such Option.

    

    

    (k)                Modification,

      Extension and Assumption of Options. Within the limitations of the Plan, the Board of Directors may modify, extend or assume outstanding Options or may accept the cancellation of outstanding Options (whether granted by the Company or another issuer)
      in return for the grant of new Options or a different type of award for the same or a different number of Shares and at the same or a different Exercise Price (if applicable). The foregoing notwithstanding, no modification of an Option shall, without
      the consent of the Optionee, impair the Optionee’s rights or increase the Optionee’s obligations under such Option.

    

    

    (l)                Company’s Right to Cancel Certain Options.
      Any other provision of the Plan or a Stock Option Agreement notwithstanding, the Company shall have the right at any time to cancel an Option that was not granted in compliance with Rule 701 under the Securities Act. Prior to canceling such Option,
      the Company shall give the Optionee not less than 30 days’ notice in writing. If the Company elects to cancel such Option, it shall deliver to the Optionee consideration with an aggregate Fair Market Value equal to the excess of (i) the Fair Market
      Value of the Shares subject to such Option as of the time of the cancellation over (ii) the Exercise Price of such Option. The consideration may be delivered in the form of cash or cash equivalents, in the form of Shares, or a combination of both. If
      the consideration would be a negative amount, such Option may be cancelled without the delivery of any consideration.

    

    

    SECTION 7.              PAYMENT FOR SHARES.

    

    

    (a)                General Rule. The entire Purchase Price or Exercise Price of Shares issued under
      the Plan shall be payable in cash or cash equivalents at the time when such Shares are purchased, except as otherwise provided in this Section 7. In addition, the Board of Directors in its sole discretion may also permit payment through any of the
      methods described in (b) through (g) below.

    

    

    (b)                Services Rendered. Shares may be awarded under the Plan in consideration of
      services rendered to the Company, a Parent or a Subsidiary prior to the award.

    

    

    (c)                Promissory Note. All or a portion of the Purchase Price or Exercise Price (as the
      case may be) of Shares issued under the Plan may be paid with a full-recourse promissory note. The Shares shall be pledged as security for payment of the principal amount of the promissory note and interest thereon. The interest rate payable under
      the terms of the promissory note shall not be less than the minimum rate (if any) required to avoid the imputation of additional interest under the Code. Subject to the foregoing, the Board of Directors (at its sole discretion) shall specify the
      term, interest rate, amortization requirements (if any) and other provisions of such note.

    

    

    
      5

      
        

    

    

    

    (d)                Surrender of Stock. All or any part of the Exercise Price may be paid by
      surrendering, or attesting to the ownership of, Shares that are already owned by the Optionee. Such Shares shall be surrendered to the Company in good form for transfer and shall be valued at their Fair Market Value as of the date when the Option is
      exercised.

    

    

    (e)             Exercise/Sale. If the Stock is publicly traded, all or part of the Exercise Price and
      any withholding taxes may be paid by the delivery (on a form prescribed by the Company) of an irrevocable direction to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales proceeds to the Company.

    

    

    (f)                Net Exercise. An Option may permit exercise through a “net exercise” arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise by the largest whole number of Shares having an
      aggregate Fair Market Value (determined by the Board of Directors as of the exercise date) that does not exceed the aggregate Exercise Price or the sum of the aggregate Exercise Price plus all or a portion of the minimum amount required to be
      withheld under applicable tax law (with the Company accepting from the Optionee payment of cash or cash equivalents to satisfy any remaining balance of the aggregate Exercise Price and, if applicable, any additional withholding obligation not
      satisfied through such reduction in Shares); provided that to the extent Shares subject to an Option are withheld in this manner, the number of Shares subject to the Option following the net exercise will be
      reduced by the sum of the number of Shares withheld and the number of Shares delivered to the Optionee as a result of the exercise.

    

    

    (g)                Other Forms of Payment. To the extent that an Award Agreement so provides, the
      Purchase Price or Exercise Price of Shares issued under the Plan may be paid in any other form permitted by the Delaware General Corporation Law, as amended.

    

    

    SECTION 8.             ADJUSTMENT

        OF SHARES.

    

    

    (a)                General.

      In the event of a subdivision of the outstanding Stock, a declaration of a dividend payable in Shares, a combination or consolidation of the outstanding Stock into a lesser number of Shares, a reclassification, or any other increase or decrease in
      the number of issued shares of Stock effected without receipt of consideration by the Company, proportionate adjustments shall automatically be made in each of (i) the number and kind of Shares available for future grants under Section 4, (ii) the
      number and kind of Shares covered by each outstanding Option and any outstanding and unexercised right to purchase Shares that has not yet expired pursuant to Section 5(b), (iii) the Exercise Price under each outstanding Option and the Purchase Price
      applicable to any unexercised stock purchase right described in clause (ii) above, and (iv) any repurchase price that applies to Shares granted under the Plan pursuant to the terms of a Company repurchase right under the applicable Award Agreement.
      In the event of a declaration of an extraordinary dividend payable in a form other than Shares in an amount that has a material effect on the Fair Market Value of the Stock, a recapitalization, a spin-off, or a similar occurrence, the Board of
      Directors at its sole discretion may make appropriate adjustments in one or more of the items listed in clauses (i) through (iv) above; provided, however, that the Board of Directors shall in any event make such adjustments as may be required by
      Section 25102(o) of the California Corporations Code. No fractional Shares shall be issued under the Plan as a result of an adjustment under this Section 8(a), although the Board of Directors in its sole discretion may make a cash payment in lieu of
      fractional Shares.

    

    

    
      6

      
        

    

    (b)                Corporate Transactions. In the event that the Company is a party to a merger or
      consolidation, or in the event of a sale of all or substantially all of the Company’s stock or assets, all Shares acquired under the Plan and all Options and other Plan awards outstanding on the effective date of the transaction shall be treated in
      the manner described in the definitive transaction agreement (or, in the event the transaction does not entail a definitive agreement to which the Company is party, in the manner determined by the Board of Directors in its capacity as administrator
      of the Plan, with such determination having final and binding effect on all parties), which agreement or determination need not treat all Options and awards (or all portions of an Option or an award) in an identical manner. The treatment specified in
      the transaction agreement or as determined by the Board of Directors may include (without limitation) one or more of the following with respect to each outstanding Option or award:

    

    

    (i)        Continuation of the Option or award by the Company (if the Company is
      the surviving corporation).

    

    

    (ii)        Assumption of the Option by the surviving corporation or its parent
      in a manner that complies with Code Section 424(a) (whether or not the Option is an ISO).

    

    

    (iii)        Substitution by the surviving corporation or its parent of a new
      option for the Option in a manner that complies with Code Section 424(a) (whether or not the Option is an ISO).

    

    

    (iv)        Cancellation of the Option and a payment to the Optionee with
      respect to each Share subject to the portion of the Option that is vested as of the transaction date equal to the excess of (A) the value, as determined by the Board of Directors in its absolute discretion, of the property (including cash) received
      by the holder of a share of Stock as a result of the transaction, over (B) the per-Share Exercise Price of the Option (such excess, the “Spread”). Such payment shall be made in the form of cash, cash
      equivalents, or securities of the surviving corporation or its parent having a value equal to the Spread. In addition, any escrow, holdback, earn-out or similar provisions in the transaction agreement may apply to such payment to the same extent and
      in the same manner as such provisions apply to the holders of Stock. If the Spread applicable to an Option is zero or a negative number, then the Option may be cancelled without making a payment to the Optionee.

    

    

    (v)        Cancellation of the Option without the payment of any
      consideration; provided that the Optionee shall be notified of such treatment and given an opportunity to exercise the Option (to the extent the Option is vested or becomes vested as of the effective date of the transaction) during a period of not
      less than five (5) business days preceding the effective date of the transaction, unless (A) a shorter period is required to permit a timely closing of the transaction and (B) such shorter period still offers the Optionee a reasonable opportunity to
      exercise the Option. Any exercise of the Option during such period may be contingent upon the closing of the transaction.

    

    

    
      7

      
        

    

    (vi)        Suspension of the Optionee’s right to exercise the Option during a
      limited period of time preceding the closing of the transaction if such suspension is administratively necessary to permit the closing of the transaction.

    

    

    (vii)      Termination of any right the Optionee has to exercise the Option
      prior to vesting in the Shares subject to the Option (i.e., “early exercise”), such that following the closing of the transaction the Option may only be exercised to the extent it is vested.

    

    

    For the avoidance of doubt, the Board of Directors has discretion to accelerate, in whole or part, the vesting and exercisability of an Option or other Plan award in connection
      with a corporate transaction covered by this Section 8(b).

    

    

    (c)                Reservation of Rights. Except as provided in this Section 8, a Participant shall
      have no rights by reason of (i) any subdivision or consolidation of shares of stock of any class, (ii) the payment of any dividend or (iii) any other increase or decrease in the number of shares of stock of any class. Any issuance by the Company of
      shares of stock of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or Exercise Price of Shares subject to an Option.   The grant
      of an Option pursuant to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or consolidate or to dissolve,
      liquidate, sell or transfer all or any part of its business or assets.

    

    

    SECTION 9.             MISCELLANEOUS

        PROVISIONS.

    

    

    (a)                Securities Law Requirements. Shares shall
      not be issued under the Plan unless, in the opinion of counsel acceptable to the Board of Directors, the issuance and delivery of such Shares comply with (or are exempt from) all applicable requirements of law, including (without limitation) the
      Securities Act, the rules and regulations promulgated thereunder, state securities laws and regulations, and the regulations of any stock exchange or other securities market on which the Company’s securities may then be traded. The Company shall not
      be liable for a failure to issue Shares as a result of such requirements.

    

    

    (b)                No Retention Rights. Nothing in the Plan or
      in any right or Option granted under the Plan shall confer upon the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or
      Subsidiary employing or retaining the Participant) or of the Participant, which rights are hereby expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without cause.

    

    

    
      8

      
        

    

    (c)               Treatment as Compensation. Any compensation
      that an individual earns or is deemed to earn under this Plan shall not be considered a part of his or her compensation for purposes of calculating contributions, accruals or benefits under any other plan or program that is maintained or funded by
      the Company, a Parent or a Subsidiary.

    

    

    (d)                Governing
      Law. The Plan and all awards, sales and grants under the Plan shall be governed by, and construed in accordance with, the laws of the State of Delaware, as such laws are applied to contracts entered into and performed in such State.

    

    

    (e)                Conditions and Restrictions on Shares.   Shares issued under
      the Plan shall be subject to such forfeiture conditions, rights of repurchase, rights of first refusal, other transfer restrictions and such other terms and conditions as the Board of Directors may determine. Such conditions and restrictions shall be
      set forth in the applicable Award Agreement and shall apply in addition to any restrictions that may apply to holders of Shares generally. In addition, Shares issued under the Plan shall be subject to conditions and restrictions imposed either by
      applicable law or by Company policy, as adopted from time to time, designed to ensure compliance with applicable law or laws with which the Company determines in its sole discretion to comply including in order to maintain any statutory, regulatory
      or tax advantage.

    

    

    	

          	(f)	
            Tax Matters.

          

    

    

    (i)        As a condition to the award, grant, issuance, vesting, purchase,
      exercise or transfer of any award, or Shares issued pursuant to any award, granted under this Plan, the Participant shall make such arrangements as the Board of Directors may require or permit for the satisfaction of any federal, state, local or
      foreign withholding tax obligations that may arise in connection with such event.

    

    

    (ii)        Unless otherwise expressly set forth in an Award Agreement,
      it is intended that awards granted under the Plan shall be exempt from Code Section 409A, and any ambiguity in the terms of an Award Agreement and the Plan shall be interpreted consistently with this intent. To the extent an award is not exempt from
      Code Section 409A (any such award, a “409A Award”), any ambiguity in the terms of such award and the Plan shall be interpreted in a manner that to the maximum extent permissible supports the award’s compliance
      with the requirements of that statute. Notwithstanding anything to the contrary permitted under the Plan, in no event shall a modification of an Award not already subject to Code Section 409A be given effect if such modification would cause the Award
      to become subject to Code Section 409A unless the parties explicitly acknowledge and consent to the modification as one having that effect. A 409A Award shall be subject to such additional rules and requirements as specified by the Board of Directors
      from time to time in order for it to comply with the requirements of Code Section 409A. In this regard, if any amount under a 409A Award is payable upon a “separation from service” to an individual who is considered a “specified employee” (as each
      term is defined under Code Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the Participant’s separation from service or (ii) the Participant’s death, but only to the extent
      such delay is necessary to prevent such payment from being subject to Section 409A(a)(1). In addition, if a transaction subject to Section 8(b) constitutes a payment event with respect to any 409A Award, then the transaction with respect to such
      award must also constitute a “change in control event” as defined in Treasury Regulation Section 1.409A- 3(i)(5) to the extent required by Code Section 409A.

    

    

    (iii)        Neither the Company nor any member of the Board of Directors shall
      have any liability to a Participant in the event an award held by the Participant fails to achieve its intended characterization under applicable tax law.

    

    

    
      9

      
        

    

    SECTION 10.             DURATION AND
        AMENDMENTS; STOCKHOLDER APPROVAL.

    

    

    (a)                Term of the Plan. The Plan, as set forth herein, shall become effective on the date
      of its adoption by the Board of Directors, subject to approval of the Company’s stockholders under Subsection (d) below. The Plan shall terminate automatically 10 years after the later of (i) the date when the Board of Directors adopted the Plan or
      (ii) the date when the Board of Directors approved the most recent increase in the number of Shares reserved under Section 4 that was also approved by the Company’s stockholders. The Plan may be terminated on any earlier date pursuant to Subsection
      (b) below.

    

    

    (b)                 Right

      to Amend or Terminate the Plan. Subject to Subsection (d) below, the Board of Directors may amend, suspend or terminate the Plan at any time and for any reason.

    

    

    (c)                 Effect

      of Amendment or Termination. No Shares shall be issued or sold and no Option granted under the Plan after the termination thereof, except upon exercise of an Option (or any other right to purchase Shares) granted under the Plan prior to such
      termination. The termination of the Plan, or any amendment thereof, shall not affect any Share previously issued or any Option previously granted under the Plan.

    

    

    (d)                Stockholder Approval.   To the
      extent required by applicable law, the Plan will be subject to approval of the Company’s stockholders within 12 months of its adoption date. To the extent required by applicable law, any amendment of the Plan will be subject to the approval of the
      Company’s stockholders within 12 months of the amendment date if it (i)  increases the number of Shares available for issuance under the Plan (except as provided in
      Section 8), or (ii) materially changes the class of persons who are eligible for the grant of ISOs. In addition, an amendment effecting any other material change to the Plan terms will be subject to approval of the Company’s stockholder only if
      required by applicable law. Stockholder approval shall not be required for any other amendment of the Plan.

    

    

    SECTION 11.             DEFINITIONS.

    

    

    (a)        “Award Agreement” means a
      Stock Grant Agreement, Stock Option Agreement or Stock Purchase Agreement.

    

    

    
      10

      
        

      

    

    
    (b)                  “Board of Directors” means the Board of Directors of the Company, as constituted from time to time.

    

    

    	

          	(c)	
            “Code” means the Internal Revenue Code of 1986, as amended.

          

    

    

    (d)                  “Committee” means a committee of the Board of Directors, as described in Section 2(a).

    

    

    	

          	(e)	
            “Company” means Zymergen, Inc., a Delaware corporation.

          

    

    

    (f)                  “Consultant” means a person, excluding Employees and Outside Directors, who performs bona fide services for the Company, a Parent3 or
      a Subsidiary as a consultant or advisor and who qualifies as a consultant or advisor under Rule 701(c)(1) of the Securities Act or under Instruction A.1.(a)(1) of Form S-8 under the Securities Act.

    

    

    (g)                  “Date of Grant” means the date of grant specified in the applicable Stock Option Agreement, which date shall be the later of (i) the date on which the Board of Directors resolved to grant the Option or (ii) the
      first day of the Optionee’s Service.

    

    

    (h)                 “Disability” means that the Optionee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment.

    

    

    (i)                   “Employee” means any individual who is a common-law employee of the Company, a Parent4 or a Subsidiary.

    

    

    	

          	(j)	
            “Exchange Act” means the Securities Exchange Act of 1934, as amended.

          

    

    

    (k)                   “Exercise Price” means the amount for which one Share may be purchased upon exercise of an Option, as specified by the Board of Directors in the applicable Stock Option Agreement.

    

    

    (l)                   “Fair Market Value” means the fair market value of a Share, as determined by the Board of Directors in good faith. Such determination shall be conclusive and binding on all persons.

    

    

    (m)                “Family Member” means (i) any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in- law, son-in-law, daughter-in-law, brother-in-law
      or sister-in-law, including adoptive relationships, (ii) any person sharing the Optionee’s household (other than a tenant or employee), (iii) a trust in which persons described in Clause (i) or (ii) have more than 50% of the beneficial interest, (iv)
      a foundation in which persons described in Clause (i) or (ii) or the Optionee control the management of assets and (v) any other entity in which persons described in Clause (i) or (ii) or the Optionee own more than 50% of the voting interests.

    

    

    
      
        
          3 Note that special considerations apply if the Company proposes to grant awards to consultant or advisor of a
            Parent company.

          

          

          4 Note that special considerations apply if the Company proposes to grant awards to an Employee of a Parent
            company.

        

      

      11

      
        

    

    

    (n)                “Grantee” means a person to whom the Board
      of Directors has awarded Shares under the Plan.

    

    

    (o)                 “ISO” means an Option that qualifies as an incentive stock option as described in Code Section 422(b). Notwithstanding its designation as an ISO, an Option that does not qualify as an ISO under applicable law shall
      be treated for all purposes as an NSO.

    

    

    (p)                 “NSO” means an Option that does not qualify as an incentive stock option as described in Code Section 422(b) or 423(b).

    

    

    (q)                 “Option” means an ISO or NSO granted under the Plan and entitling the holder to purchase Shares.

    

    

    	

          	(r)	
            “Optionee” means a person who holds an Option.

          

    

    

    	

          	(s)	
            “Outside Director” means a member of the Board of Directors who is not an Employee.

          

    

    

    
      (t)                  “Parent” means any corporation (other than the Company) in an unbroken
        chain of corporations ending with the Company, if each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. A
        corporation that attains the status of a Parent on a date after the adoption of the Plan shall be considered a Parent commencing as of such date.

    

    

    	

          	(u)	
            “Participant” means a Grantee, Optionee or Purchaser.

          

    

    

    	

          	(v)	
            “Plan” means this Zymergen, Inc. 2014 Stock Plan.

          

    

    

    (w)                 “Purchase Price” means the consideration for which one Share may be acquired under the Plan (other than upon exercise of an Option), as specified by the Board of Directors.

    

    

    (x)                 “Purchaser” means a person to whom the Board of Directors has offered the right to purchase Shares under the Plan (other than upon exercise of an Option).

    

    

    	

          	(y)	
            “Securities Act” means the Securities Act of 1933, as amended.

          

    

    

    (z)                  “Service” means service as an Employee, Outside Director or Consultant. 

     

    

    (aa)               “Share” means one share
      of Stock, as adjusted in accordance with Section 8 (if applicable).

    

    

    (bb)               “Stock”
      means the Common Stock of the Company.

    

    

    (cc)               “Stock Grant Agreement” means the agreement
      between the Company and a Grantee who is awarded Shares under the Plan that contains the terms, conditions and restrictions pertaining to the award of such Shares.

    

    

    
      12

      
        

    

    (dd)                 “Stock Option Agreement” means the
      agreement between the Company and an Optionee that contains the terms, conditions and restrictions pertaining to the Optionee’s Option.

    

    

    (ee)                “Stock Purchase Agreement” means the
      agreement between the Company and a Purchaser who purchases Shares under the Plan that contains the terms, conditions and restrictions pertaining to the purchase of such Shares.

    

    

    (ff)                “Subsidiary” means any corporation (other
      than the Company) in an unbroken chain of corporations beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing 50% or more of the total combined voting power of all classes
      of stock in one of the other corporations in such chain. A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such date.

    

    

    
      13

      
        

    

    EXHIBIT A

    

    

    SCHEDULE OF SHARES RESERVED FOR ISSUANCE UNDER THE PLAN

    

    

    

    

    	
            Date of Board Approval

          	 	
            Date of Stockholder Approval

          	 	
            Number of Shares Added

          	 	
            Cumulative Number of Shares

          
	
             

             

            July 21, 2014

          	 	
             

             

            September 15, 2014

          	 	
             

             

            Not Applicable

          	 	
             

             

            1,600,000

          
	
            September 15, 2014

          	 	
            September 15, 2014

          	 	
            (25,000)

          	 	
            1,575,000

          
	
            June 4, 2015

          	 	
            June 4, 2015

          	 	
            2,103,630

          	 	
            3,678,630

          
	
            February 18, 2016

          	 	
            March 16, 2016

          	 	
            Forward Stock Split

          	 	
            11,035,890

          
	
            April 14, 2016

          	 	
            N/A

          	 	
            (75,000)

          	 	
            10,960,890

          
	
            October 6, 2016

          	 	
            October 6, 2016

          	 	
            8,171,234

          	 	
            19,132,124

          
	
            October 22, 2018

          	 	
            October 26, 2018

          	 	
            11,430,577

          	 	
            30,562,701

          
	
            July 28, 2020

          	 	
            July 28, 2020

          	 	
            5,000,000

          	 	
            35,562,701

          

    

    

    

    

    SUMMARY OF MODIFICATIONS AND AMENDMENTS TO THE PLAN

    

    

    The following is a summary of material modifications made to the Plan (including any material deviations from the Gunderson Dettmer precedent form used to create the Plan):

    

    

    A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]